Outcomes, costs, and policy caution: A commentary on the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)

Archives of General Psychiatry

Volumn 63, Issue 10, 2006, Pages 1074-1076

  Rosenheck, Robert A ^a  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; RISPERIDONE; SULPIRIDE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG POTENCY; HEALTH CARE POLICY; HUMAN; META ANALYSIS; METABOLIC SYNDROME X; NOTE; QUALITY OF LIFE; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; GREAT BRITAIN; HEALTH POLICY; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES;

EID: 33749325996     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.63.10.1074     Document Type: Note

References (21)

1. Duggan M. Do new prescription drugs pay for themselves? the case of second-generation antipsychotics. J Health Econ. 2005;24:1-31.
2. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
3. 1999 Drug Topics Red Book. Montvale, NJ: Medical Economics Co; 1999.
4. Practice Guideline for the Treatment of Patients With Schizophrenia. 2nd ed. Washington, DC: American Psychiatric Association; 2004:16.
5. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. May 2002. National Institute for Health and Clinical Excellence Web site. http://www.nice.org.uk/. Accessed March 1, 2006.
6. Miller AL, Hall CS, Buchanan RW, Buckley PF, Chiles J, Conley RR, Crismon ML, Ereshefsky L, Essock SM, Finnerty M, Marder SR, Miller D, McEvoy J, Rush AJ, Saeed SA, Schooler NR, Shon S, Stroup S, Tarin-Godoy B. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004;65:500-508.
7. Treatment of schizophrenia 1999: the expert consensus guideline series. J Clin Psychiatry. 1999;60(suppl 11):3-80.
8. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SW. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079-1087.
9. Lavori PW. Clinical trials in psychiatry: should protocol deviation censor patient data? Neuropsychopharmacology. 1992;6:39-48, discussion 49-63.
10. Soares BG, Fenton M, Chue P. Sulpiride for schizophrenia. Cochrane Database Syst Rev. 2000;(2):CD001162.
11. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V; Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. JAMA. 2003;290:2693-2702.
12. Lieberman JA, Stroup TS, McEvoy J, Swartz M, Rosenheck R, Perkins D, Keefe RSE, Davis S, Davis CE, Lebowitz B, Severe J, Hsiao J; the CATIE Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial. N Engl J Med. 2005;353:1209-1223.
13. Rosenheck RA. Efficacy vs effectiveness of second generation antipsychotics: haloperidol without prophylactic anticholinergics as a comparator. Psychiatr Serv. 2005;56:85-92.
14. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414-425.
15. Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V, McCreadie R. Nithsdale schizophrenia surveys 23: movement disorders. Br J Psychiatry. 2002;181:422-427.
16. Lee PE, Sykora K, Gill SS, Mamdani M, Marras C, Anderson G, Shubnan KI, Stukel T, Normand S-L, Rochon P. Antipsychotic medication and drug-induced movement disorder: a population-based cohort study in older adults. J Am Geriatr Soc. 2005;53:1374-1379.
17. Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, Normand S-LT, Mamdani M, Lee PE, Li P, Bronskill SE, Marras C, Gurwitz JH. Atypical antipsychotics and parkinsonism. Arch Intern Med. 2005;165:1882-1888.
18. Woods S. Tardive dyskinesia dead or alive? Paper presented at: Institute on Psychiatric Services; October 6, 2005; San Diego, Calif.
19. Daniels N, Sabin J. Setting Limits Fairly: Can We Learn to Share Medical Resources? New York, NY: Oxford; 2003.
20. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-tohead comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163:185-194.
21. Reinhardt UE. An information infrastructure for the pharmaceutical market. Health Aff (Millwood). 2004;23:107-112.